GLPG3970
CAS No. 2403733-82-2
GLPG3970( —— )
Catalog No. M36521 CAS No. 2403733-82-2
GLPG3970 GLPG3970 is a novel orally available selective dual SIK2/SIK3 inhibitor.GLPG3970 has potential anti-inflammatory activity for the study of autoimmune diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 207 | Get Quote |
|
| 5MG | 316 | Get Quote |
|
| 10MG | 470 | Get Quote |
|
| 25MG | 727 | Get Quote |
|
| 50MG | 1030 | Get Quote |
|
| 100MG | 1341 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGLPG3970
-
NoteResearch use only, not for human use.
-
Brief DescriptionGLPG3970 GLPG3970 is a novel orally available selective dual SIK2/SIK3 inhibitor.GLPG3970 has potential anti-inflammatory activity for the study of autoimmune diseases.
-
DescriptionGLPG3970 (compound 88) is a first-in-class SIK2/SIK3 inhibitor. GLPG3970 can be used for the research of inflammation and autoimmune disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAutophagy
-
TargetSIK
-
RecptorSIK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2403733-82-2
-
Formula Weight504.5
-
Molecular FormulaC25H27F3N4O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (198.22 mM; Ultrasonic )
-
SMILESO=C1C=2C(OC)=CC(=CC2CCN1CC(F)(F)F)C3=CN=C4C=C(OCCN5CCOCC5)C=CN43
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. DESROY N, et al. NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES. WO/2019/238424. 2019.
molnova catalog
related products
-
YKL-05-099
YKL-05-099 (YKL 05-099) is a novel potent, selective pan-SIK inhibitor with IC50 of 10, 40 and 30 nM for SIK1, 2 and 3, respectively.
-
WH-4-025
WH-4-025 is a?Salt-inducible kinase (SIK)?inhibitor.
-
MRT 199665
MRT 199665 is a potent salt-inducible kinases (SIKs) inhibitor with IC50 of 110, 12, 43 nM for SIK1,2,3 respectively.
Cart
sales@molnova.com